Should you buy Denali Therapeutics stock now?
Yes, the technical signal for Denali Therapeutics is currently BUY. Denali Therapeutics trades at $24.46 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.059 with falling momentum (signal: 0.098); RSI is at 54.3 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $34.31 points to 40.3% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Denali Therapeutics stock?
The average analyst price target for Denali Therapeutics is $34.31. The current price is $24.46, which gives an upside of 40.3%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $30.88 and $37.74.
Is Denali Therapeutics a dividend stock?
No, Denali Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Denali Therapeutics stock?
Denali Therapeutics is rated as a stock with high risk. the annual standard deviation is 57.9%, which classifies the stock as high risk.
Is Denali Therapeutics overvalued?
No, Denali Therapeutics is considered undervalued based on the analyst price target (40.3% upside). Denali Therapeutics has the following valuation ratios: a P/S ratio of 3,643.6, a P/B ratio of 3.9. The analyst price target suggests that the stock is undervalued by 40.3%.
Is Denali Therapeutics overbought?
No, Denali Therapeutics is not overbought. RSI is at 54.3 (neutral zone). The technical indicators show: RSI is at 54.3 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 2.2% above the 20-day average (short-term uptrend). In addition, MACD is positive, but momentum is falling.
When is the next Denali Therapeutics earnings report?
Denali Therapeutics reports earnings TODAY, August 6, 2026! The stock currently trades at $24.46. Watch how the price reacts after the release.
Is Denali Therapeutics shorted?
Yes, Denali Therapeutics is shorted with 10.7% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Denali Therapeutics stock?
No, insiders are not buying Denali Therapeutics shares – they are net sellers. Across the last 20 reported transactions, the split is 1 purchases and 19 sales, with a net 17,399,670 $ sold. Active sellers include Watts Ryan J., Schuth Alexander O., Ryan J Watts and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Denali Therapeutics a good stock?
Based on our total score, Denali Therapeutics is rated as a poor stock with a total score of 32 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 10/100, Quality: 6/100, Momentum: 81/100. In addition: analysts see 40.3% upside to the price target; technical signal: Strong Buy. Whether Denali Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Denali Therapeutics stock?
The outlook for Denali Therapeutics based on current data: the average analyst price target is $34.31 (+40.3%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 8/6/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Denali Therapeutics stock rising?
Denali Therapeutics is rising right now. The technical indicators show: the price is 2.2% above the 20-day average; short interest is 10.7% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Denali Therapeutics go?
The average analyst price target for Denali Therapeutics is $34.31, which corresponds to a potential gain of 40.3% from the current price of $24.46. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Denali Therapeutics fall?
We lack enough history to give a specific floor for Denali Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Denali Therapeutics do?
Denali Therapeutics laver medicin mod nervesygdomme og sjældne stofskiftesygdomme. De udvikler behandlinger, der kan trænge ind i hjernen, hvilket er ret svært. Denali fokuserer især på at få deres lægemidler frem til de steder, hvor sygdommen opstår.
De har en stor pipeline ... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Denali Therapeutics as an investment.
Did Denali Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Denali Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Denali Therapeutics making money or losing money?
We have no current profitability data for Denali Therapeutics. See the latest report in the earnings history above.
Can Denali Therapeutics go bankrupt?
The bankruptcy risk of Denali Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -0.72 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. Debt relative to equity is 12% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Denali Therapeutics have a lot of debt?
No, Denali Therapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 12%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
